Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock, $0.0001 Par Value Per Share
-
Shares outstanding
-
107,800,271
-
Number of holders
-
200
-
Total 13F shares, excl. options
-
68,372,935
-
Shares change
-
+227,002
-
Total reported value, excl. options
-
$3,578,473,075
-
Value change
-
+$18,800,232
-
Put/Call ratio
-
49%
-
Number of buys
-
92
-
Number of sells
-
-84
-
Price
-
$52.34
Significant Holders of Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) as of Q4 2021
241 filings reported holding ITCI - Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share as of Q4 2021.
Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) has 200 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 68,372,935 shares
of 107,800,271 outstanding shares and own 63.43% of the company stock.
Largest 10 shareholders include FMR LLC (10,961,969 shares), WASATCH ADVISORS INC (8,235,171 shares), VANGUARD GROUP INC (6,876,201 shares), BlackRock Inc. (5,721,766 shares), Bellevue Group AG (3,628,919 shares), MARSHALL WACE, LLP (2,388,294 shares), LORD, ABBETT & CO. LLC (2,130,820 shares), STATE STREET CORP (1,522,638 shares), PICTET ASSET MANAGEMENT SA (1,454,874 shares), and TimesSquare Capital Management, LLC (1,343,965 shares).
This table shows the top 200 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.